Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial.
Bobak Heydari,Shuaib A Abdullah,James V. Pottala,Ravi V. Shah,Siddique Abbasi,Damien Mandry,Sanjeev A. Francis,Heidi Lumish,Brian B. Ghoshhajra,Udo Hoffmann,Evan Appelbaum,Jiazhuo H. Feng,Ron Blankstein,Michael L. Steigner,Joseph P. McConnell,William H. Harris,Elliott M. Antman,Michael Jerosch-Herold,Raymond Y. Kwong +18 more
Reads0
Chats0
TLDR
Treatment of patients with acute myocardial infarction with high-dose omega-3 fatty acids was associated with reduction of adverse left ventricular remodeling, noninfarctMyocardial fibrosis, and serum biomarkers of systemic inflammation beyond current guideline-based standard of care.Abstract:
Background:Omega-3 fatty acids from fish oil have been associated with beneficial cardiovascular effects, but their role in modifying cardiac structures and tissue characteristics in patients who have had an acute myocardial infarction while receiving current guideline-based therapy remains unknown. Methods:In a multicenter, double-blind, placebo-controlled trial, participants presenting with an acute myocardial infarction were randomly assigned 1:1 to 6 months of high-dose omega-3 fatty acids (n=180) or placebo (n=178). Cardiac magnetic resonance imaging was used to assess cardiac structure and tissue characteristics at baseline and after study therapy. The primary study endpoint was change in left ventricular systolic volume index. Secondary endpoints included change in noninfarct myocardial fibrosis, left ventricular ejection fraction, and infarct size. Results:By intention-to-treat analysis, patients randomly assigned to omega-3 fatty acids experienced a significant reduction of left ventricular systo...read more
Citations
More filters
Journal ArticleDOI
American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Paul S. Jellinger,Yehuda Handelsman,Paul D. Rosenblit,Zachary T. Bloomgarden,Vivian Fonseca,Alan J. Garber,George Grunberger,Chris K. Guerin,David S.H. Bell,Jeffrey I. Mechanick,Rachel Pessah-Pollack,Kathleen Wyne,Donald A. Smith,Eliot A. Brinton,Sergio Fazio,Michael H. Davidson,Farhad Zangeneh,Michael A. Bush +17 more
TL;DR: This CPG is a practical tool that endocrinologists, other health care professionals, health-related organizations, and regulatory bodies can use to reduce the risks and consequences of dyslipidemia.
Journal ArticleDOI
Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives
TL;DR: Current knowledge of the mechanisms and detrimental consequences of myocardial interstitial fibrosis are summarized, the potential of circulating and imaging biomarkers available to recognize different phenotypes of this lesion and track their clinical evolution are discussed, and the currently available and potential future therapies that allow its individualized management in heart failure patients are reviewed.
Journal ArticleDOI
Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases.
TL;DR: Based on preclinical studies, these omega‐3 epoxyeicosanoids display cardioprotective, vasodilatory, anti‐inflammatory, and anti‐allergic properties that contribute to the beneficial effects of n‐3 LC‐PUFAs in diverse disease conditions ranging from cardiac disease, bronchial disorders, and intraocular neovascularization, to allergic intestinal inflammation and inflammatory pain.
Journal ArticleDOI
Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome
Erik B. Schelbert,Yaron Fridman,Timothy C. Wong,Hussein Abu Daya,Kayla Piehler,Ajay Kadakkal,Christopher A. Miller,Martin Ugander,Maren Maanja,Peter Kellman,Dipan J. Shah,Kaleab Z. Abebe,Marc A. Simon,Giovanni Quarta,Michele Senni,Javed Butler,Javier Díez,Javier Díez,Margaret M. Redfield,Mihai Gheorghiade +19 more
TL;DR: Investigating whether myocardial fibrosis (MF) is similarly prevalent both in those with HFpEF and those at risk forHFpEF, similarly associating with disease severity and outcomes found it to be similarly prevalent.
Journal ArticleDOI
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial.
Are A Kalstad,Are A Kalstad,Peder L. Myhre,Peder L. Myhre,Kristian Laake,Sjur H Tveit,Sjur H Tveit,Erik Berg Schmidt,Paal Smith,Paal Smith,Dennis W.T. Nilsen,Dennis W.T. Nilsen,Arnljot Tveit,Arnljot Tveit,Morten W. Fagerland,Svein Solheim,Ingebjørg Seljeflot,Ingebjørg Seljeflot,Harald Arnesen,Harald Arnesen,Omemi Investigators +20 more
TL;DR: The hypothesis was that daily addition of 1.8g n-3 PUFA to standard of care secondary prophylaxis in elderly patients who have survived an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up.
References
More filters
Journal ArticleDOI
Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart A Statement for Healthcare Professionals From the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association
Manuel D. Cerqueira,Neil J. Weissman,Vasken Dilsizian,Alice K. Jacobs,Sanjiv Kaul,Warren K. Laskey,Dudley J. Pennell,John A. Rumberger,Thomas J. Ryan,Mario S. Verani +9 more
TL;DR: Attempts to standardize options for all cardiac imaging modalities should be based on the sound principles that have evolved from cardiac anatomy and clinical needs, and selection of standardized methods must bebased on the following criteria.
Journal ArticleDOI
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. results of the survival and ventricular enlargement trial
Marc A. Pfeffer,Eugene Braunwald,Lemuel A. Moyé,Lofty L. Basta,Edward J. Brown,Thomas E. Cuddy,Barry R. Davis,Edward M. Geltman,Steven Goldman,Greg C. Flaker,Marc Klein,Gervasio A. Lamas,Milton Packer,Jacques R. Rouleau,Jean L. Rouleau,John D. Rutherford,John H. Wertheimer,C. Morton Hawkins +17 more
TL;DR: In patients with asymptomatic left ventricular dysfunction after myocardial infarction, long-term administration of captopril was associated with an improvement in survival and reduced morbidity and mortality due to major cardiovascular events.
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
Patrick T. O'Gara,Frederick G. Kushner,Deborah D. Ascheim,Donald E. Casey,Mina K. Chung,James A. de Lemos,Steven M. Ettinger,James C. Fang,Francis M. Fesmire,Barry A. Franklin,Christopher B. Granger,Harlan M. Krumholz,Jane A. Linderbaum,David A. Morrow,L. Kristin Newby,Joseph P. Ornato,Narith N. Ou,Martha J. Radford,Jacqueline E. Tamis-Holland,Carl L. Tommaso,Cynthia M. Tracy,Y. Joseph Woo,David Zhao +22 more
TL;DR: The 2017-18 FAHA/FACC/FAHA Education and Research Grants will be focused on advancing the profession’s understanding of central nervous system disorders and the management of post-traumatic stress disorder.
Book
Applied Longitudinal Analysis
TL;DR: In this article, the authors present an overview of linear models for long-term continuous-time data and compare them with generalized linear mixed effects models for estimating the covariance and the mean.
Journal ArticleDOI
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
Marc A. Pfeffer,Eugene Braunwald +1 more
TL;DR: The extent of ventricular enlargement after infarction is related to the magnitude of the initial damage to the myocardium and, although an increase in cavity size tends to restore stroke volume despite a persistently depressed ejection fraction, ventricular dilation has been associated with a reduction in survival.